Literature DB >> 10097910

Long-acting insulin analogs.

R H Rosskamp1, G Park.   

Abstract

Once daily injection of existing intermediate/long-acting insulin preparations does not provide a 24-h basal insulinemia in most patients. High variability, pronounced insulin peaks, and (as a result) a high risk of nocturnal hypoglycemia only poorly simulate normal physiology. One principle to prolong insulin action is the shift of the isoelectric point of insulin towards neutral. One example is HOE 901, which shows in healthy volunteers a constant peakless profile over the entire 24-h clamp period. In 4-week trials in comparison to NPH insulin, significant lower fasting plasma glucose levels were achieved with lower rates of nocturnal hypoglycemia. Another principle to prolong insulin action is the use of soluble fatty acid acylated insulins that are bound to albumin after absorption. The combination of long- and short-acting insulins might provide the tools towards the final goal of achieving sustained normoglycemia in diabetic patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10097910

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  16 in total

Review 1.  Modern pharmacotherapies for type 2 diabetes mellitus.

Authors:  S H Hsia
Journal:  J Natl Med Assoc       Date:  2001-09       Impact factor: 1.798

2.  In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.

Authors:  Mark R Sommerfeld; Günter Müller; Georg Tschank; Gerhard Seipke; Paul Habermann; Roland Kurrle; Norbert Tennagels
Journal:  PLoS One       Date:  2010-03-04       Impact factor: 3.240

3.  Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp.

Authors:  S V M Hordern; J E Wright; A M Umpleby; F Shojaee-Moradie; J Amiss; D L Russell-Jones
Journal:  Diabetologia       Date:  2005-02-24       Impact factor: 10.122

4.  Insulin glargine.

Authors:  P S Gillies; D P Figgitt; H M Lamb
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

Review 5.  A critical appraisal of the role of insulin analogues in the management of diabetes mellitus.

Authors:  Ralph Oiknine; Marla Bernbaum; Arshag D Mooradian
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Comparison of insulins detemir and glargine: effects on glucose disposal, hepatic glucose release and the central nervous system.

Authors:  M C Moore; M S Smith; M K Turney; S Boysen; P E Williams
Journal:  Diabetes Obes Metab       Date:  2011-09       Impact factor: 6.577

Review 7.  A rational approach to drug therapy of type 2 diabetes mellitus.

Authors:  J M Chehade; A D Mooradian
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 8.  Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus.

Authors:  Therese M Chapman; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Dose-response effects of insulin glargine in type 2 diabetes.

Authors:  Zhihui Wang; Maka S Hedrington; Nino Gogitidze Joy; Vanessa J Briscoe; M Antoinette Richardson; Lisa Younk; Wendell Nicholson; Donna B Tate; Stephen N Davis
Journal:  Diabetes Care       Date:  2010-03-31       Impact factor: 17.152

10.  Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients.

Authors:  Edoardo Mannucci; Matteo Monami; Daniela Balzi; Barbara Cresci; Laura Pala; Cecilia Melani; Caterina Lamanna; Ilaria Bracali; Michela Bigiarini; Alessandro Barchielli; Niccolo Marchionni; Carlo Maria Rotella
Journal:  Diabetes Care       Date:  2010-06-14       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.